ASP 6294Alternative Names: ASP6294
Latest Information Update: 16 Jan 2017
At a glance
- Originator Astellas Pharma
- Class Urologics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Interstitial cystitis
Most Recent Events
- 09 Jan 2017 Astellas Pharma completes a phase-I trial in Interstitial cystitis (In volunteers) in United Kingdom (IV, SC) (NCT02681861)
- 01 Jan 2016 Phase-I clinical trials in Interstitial cystitis (In volunteers) in United Kingdom (IV, SC) (NCT02681861)